A new orally active anti-rheumatic drug targets IL-15 and IL-17

Japanese Journal of Clinical Immunology

Volumn 30, Issue 5, 2007, Pages 375-382

  Chiba, Kenji ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

CIA; IL 15; IL 17; RA; Y 320

Indexed keywords

ANTIRHEUMATIC AGENT; INTERLEUKIN 15; INTERLEUKIN 17; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTHRITIS; DRUG DELIVERY SYSTEM; IMMUNOLOGY; MACACA; MOUSE; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DRUG DELIVERY SYSTEMS; INTERLEUKIN-15; INTERLEUKIN-17; MACACA MULATTA; MICE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38449114897     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.30.375     Document Type: Article

References (22)

1. E. Karouzakis, M. Meidhart, R. E. Gay, and S. Gay.: Molecular and cellular basis of rheumatoid joint destruction. Immunol. Lett. 106: 8–13, 2006.
2. B. Baslund, N. Tvede, B. D. Samsoe, P. Larsson, G. Panayi, J. Petersen, L. J. Petersen, F. J. M. Beurskens, J. Schuurman, J. G. J. van de Winkel, P.W.H.I. Parren, J. A. Gracie, S. Jongbloed, F. Y. Liew, and I. B. McInnes.: Targeting interleukin-15 in patients with rheumatoid arthritis. A proof-of-concept study. Arthritis Rheum. 52: 2686–2692, 2005.
3. D. M. Anderson, S. Kumaki, M. Ahdieh, J. Bertles, M. Tometsko, A. Loomis, J. Giri, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, V. Valentine, D. N. Shapiro, S. W. Morris, L. S. Park, and D. Cosman.: Functional characterization of the human interleukin-15 receptor a chain and close linkage of IL-15RA and IL-2RA genes. J. Biol. Chem. 270: 29862–29869, 1995.
4. I. B. McInnes, J. A. Mughales, M. Field, B. P. Leung, F.-P. Huang, R. Dixon. R.D. Sturrock, P. C. Wilkinson, and T. Y. Liew.: The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. 2: 175–182, 1997.
5. I. B. McInnes, B. P. Leung, R. D. Sturrock, M. Field, and F. Y. Liew.: Interleukin-15 mediated T cell-dependent regulation of tumor necrosis factor-a production in rheumatoid arthritis. Nat. Med. 3: 189–195, 1997.
6. M. Ziolkowska, A. Koc, G. Luszczykiewicz, K. K. Pietrzak, E. Klimczak, H. C. Sadowska, and W. Maslinski.: High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol. 164: 2832–2838, 2000.
7. H17 and regulatory T cells. Nature 441: 235–238, 2006.
8. H2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13: 139–145, 2007.
9. E. Lubberts, M. I. Koenders, B. Oppers-Walgreen, L. van den Bersselaar, C. J. J. Coenender Roo, L. A. B. Joosten, and W. B. van den Berg.: Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50: 650–659, 2004.
10. S. Nakae, A. Nambu, K. Sudo, and Y. Iwakura.: Suppression of immune induction of collagen-induced arthritis in IL-17-deicient mice. J. Immunol. 171: 6173–6177, 2003.
11. H. Ushio, S. Ishibuchi, K. Adachi, K. Oshita, and K. Chiba.: Phenylpyrazoleanilide as a new class of immunomodulator: Part 1. Biomed. Chem. Lett. In press.
12. H. Ushio, K. Adachi, K. Oshita, and K. Chiba.: Phenylpyrazoleanilide as a new class of immunomodulator: Part 2 discovery of a new candidate, Y-320. Biomed. Chem. Lett. In press. 29: 212, 2006.
13. + T cell accumulation in rheumatoid arthritis synovium. J. Immunol. 165: 6590–6598, 2000.
14. K. Oshita, H. Kataoka, N. Seki, Y. Harada, K. Sugahara, and K. Chiba.: Y-320, a new class of immunomodulator. I. Y-320 inhibits IL-17 production from CD4 T cells stimulated with IL-15. 36: 290, 3-I-W47-19-P, 2006.
15. N. Seki, N. Sato, Y. Maeda, K. Oshita, H. Kataoka, and K. Chiba.: Y-320, a new class of immunomodulator. IV. Y-320 inhibits IL-17 production from memory T cells stimulated with IL-15 or IL-23. 36: 290, 2006.
16. N. Seki, K. Oshita, N. Sato, H. Kataoka, Y. Harada, K. Sugahara, and K. Chiba.: Y-320, a new class of immunomodulator, inhibits IL-17 production. I. Y-320 inhibits IL-17 production from IL-15-activated T cells. The EULAR Journal 66: 151, THU0086, 2007.
17. S. Kumaki, N. Ishii, M. Minegishi, S. Tsuchiya, D. Cosman, K. Sugamura, and T. Konno.: Functional role of interleukin-4 (IL-4) and IL-7 in the development of X-linked severe combines immunodeiciency. Blood, 93: 607–612, 1999.
18. H. Kataoka, K. Oshita, M. Ohtsuki, N. Sato, Y. Hoshino, K. Sugahara, and K. Chiba.: Y-320, a new class of immunomodulator. II. Y-320 ameliorates type II collagen-induced arthritis in mice.36: 290, 3-I-W47-20-P, 2006.
19. H. Kataoka, N. Sato, N. Seki, K. Shimano, K. Sugahara, and K. Chiba.: Y-320, a new class of immunomodulator, inhibits IL-17 production. II. Y-320 ameliorates type II collagne-induced arthritis in mice. The EULAR Journal 66: 143, THU0059, 2007.
20. N. Sato, N. Seki, K. Shimano, Y. Hoshino, K. Sugahara, and K. Chiba.: Y-320, a new class of immunomodulator. III. Y-320 inhibits IL-17 production in type II collagen-induced arthritis in mice.36: 291, 3-I-W47-21-P, 2006.
21. Y. Hoshino, N. Sato, K. Sugahara, and K. Chiba.: Y-320, a new class of immunomodulator. V. Therapeutic efect of Y-320 on type II collagen-induced arthritis in cynomolgus monkeys. 36: 291, 3-I-W47-23-O/P, 2006.
22. N. Sato, H. Kataoka, K. Oshita, M. Ohtsuki, K. Sugahara, and K. Chiba.: Y-320, a new class of immunomodulator, inhibits IL-17 production. III. Therapeutic effect of Y-320 on type II collagen-induced arthritis in cynomolgus monkeys. The EULAR Journal 66: 150, THU0084, 2007.